A carregar...
Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
INTRODUCTION: The treatment of lung cancer is not defined in the third-line setting and remains an unanswered question. Erlotinib is the only drug approved in the third-line setting. With the introduction of effective first- and second-line therapies, more and more patients warrant an effective thir...
Na minha lista:
| Publicado no: | South Asian J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer - Medknow
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6956591/ https://ncbi.nlm.nih.gov/pubmed/31956622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sajc.sajc_28_19 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|